Dec 13, 2021
VIRALEZE™ successfully launched in Vietnam (ASX Announcement)
- VIRALEZE™ antiviral nasal spray successfully launched in Vietnam last week
- Starpharma has received VIRALEZE™ orders in excess of A$2 million for Vietnam, since late October
Melbourne, Australia; 13 December 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that since signing the commercial arrangement for VIRALEZE™ antiviral nasal spray in Vietnam, the company has received orders in excess of A$2 million, since late October. Some orders have already been delivered with further product expected to be delivered in the New Year. VIRALEZE™ successfully launched in Vietnam last week, with the formal launch events attended by clinicians, healthcare professionals, politicians, and media representatives from over 30 news channels.
VIRALEZE™ is available in Vietnam to retail consumers, clinics, hospitals and pharmacies through local medical distribution networks in Vietnam. Vietnam, which has a population of approximately 98 million, is experiencing a significant Delta outbreak with just over half of its population vaccinated.
Dr Jackie Fairley, Starpharma CEO commented: “We are delighted that the launch of VIRALEZE™ in Vietnam was so successful and has already generated significant sales. This demand is indicative of the significant need for products like VIRALEZE™, which are complimentary to vaccines and other preventative strategies”.
Starpharma’s distribution arrangement for VIRALEZE™ in Vietnam is with HealthCo Australia, with Truong Bao Land, and Nam Thanh Trade and Medical Services Company Limited responsible for importation and distribution locally in Vietnam. Starpharma continues negotiations with potential commercial partners elsewhere in multiple countries in Europe, Asia, and the Middle East.
VIRALEZE™ Antiviral Nasal Spray
VIRALEZE™ is a broad-spectrum antiviral nasal spray. The antiviral agent in VIRALEZE™, referred to as SPL7013, has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses (including influenza and RSV) and multiple variants of SARS-CoV-2, including inactivation of >99.9% of the highly infectious Delta variant, in laboratory studies. VIRALEZE™ is applied in the nose to provide a physical barrier - between viruses and the nasal mucous membrane - that traps and irreversibly inactivates virus. Importantly, the mechanism of action of VIRALEZE™ means that mutations of the spike protein that make SARS-CoV-2 more infectious, as occurred for the Delta strain, appear to make the virus more susceptible to trapping and blocking by SPL7013.
VIRALEZE™ is registered in Europe, Vietnam, India and New Zealand, and available in certain markets online. In addition to the supply and distribution arrangements in Vietnam, VIRALEZE™ is also partnered with LloydsPharmacy in the UK, ADMENTA Italia Group in Italy, and Starpharma is in advanced discussions with potential commercial partners in other countries. VIRALEZE™ is not registered for sale or supply in Australia.
Starpharma acknowledges the $1 million in funding for the development of VIRALEZE™ provided by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest. Delivered by MTPConnect, the Australian Government's BTB program is a $22.3 million MRFF initiative that provides up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality
Download full announcement here: VIRALEZE™ successfully launched in Vietnam (PDF 215KB)